Latest clinical and nursing programme

Day 1

0930
Welcome & opening remarks
Mark Gilchrist - View Bio

Plenary - Can we tell you a story? Why we are here - an OPAT journey from the clinician and patient perspectives
0940
Fail better - the clinical story
Aisling Brown - View Bio
1000
Patient perspective - my experience of a complex treatment
Joseph Passingham
1010
Q&A

Plenary Session: Debate - Oral versus IV: Implications of the OVIVA Study
Chair: Dr Matthew Dryden
1030
Argument for early switching
Matt Scarborough - View Bio
1045
The role of IV therapy in Bone and joint infection
Andrew Seaton - View Bio
1100
Questions from the floor

1130
Refreshments and networking

Parallel session one - A holistic approach to OPAT using Standards for Infusion Therapy
1200
An introduction to the development of RCN standards and rationale for Infusion therapy
Suman Shrestha
1230
Infusion therapy; the patient perspective
Lynne Currie - View Bio
1255
Application of the infusion standards into practice 
Sue Rowlands
1320
Q&A
Parallel session two - Free paper session
Chair: Dr Sanjay Patel
1200
Retrospective Audit of Outpatient Antimicrobial Parenteral Antimicrobial Therapy (OPAT) for Infective Endocarditis: 2014 – 2017 
Dr Karen Burns - View Bio
1215
The role of a Pharmacist Advanced Clinical Practitioner (ACP) within OPAT 
1230
Experience in  the management of acute exacerbations of Bronchiectasis; a local 
1245
Maximising the opportunity of a self-administration OPAT pathway 
1300
Malignant Otitis External: OPAT Experience at Nottingham 

1330
Lunch and poster viewing

Plenary sponsored symposium
1415
Cardiome

Keynote lecture
1500
"OPAT the time for change in provider delivery" 
Andrew Davies

Parallel session one - Challenges in establishing or expanding an OPAT service
Chair: Dr Susan Snape
1530
The importance of a clinical champions and an MDT approach
1550
Chief Executive Officer view - what we need to hear
1600
Chief Finance Officer view - talking finances
1610
Panel discussion with Q&A (Chair and speakers)
Parallel session two - Vascular Health and Vascular Access Issues
Chair: Andrew Jackson
1500
Patient experience with vascular access
Mrs Linda Kelly - View Bio
1525
Infusion safety from a unique perspective
1620
Q&A

1630
Refreshments and networking

Parallel session one - New and novel OPAT therapies and strategies
1700
Developing ambulatory OPAT in paediatric care
Lucy Hinds
1720
24 hour infusion - a new OPAT pathway for diabetic foot?
Naomi Fleming
1740
Dalbavacin & OPAT - case series
Neil Ritchie, QEUH, Glasgow
1800
Panel led discussion / Q&A
Parallel session two - Vascular Health and Vascular Access Issues … continued
Chair: Dr Sanjay Patel
1700
Innovation and technology in vascular access
1725
Clinical outcomes of midlines in community and hospital practice
1750
Q&A

1820
Welcome drinks, networking and poster presentations
Day 2

0730
Breakfast refreshments

Plenary session: Clinical case studies: expert panel discussion
Chair: Dr Sanjay Patel
0745
Case studies
Eoghan de Barra - View Bio
0810
Case studies
Gavin Barlow - View Bio
0830
Expert panel discussion

Parallel session one - Treatments and pathways
Chair: Mr Mark Gilchrist
0900
How the introduction of elastomeric devices has improved OPAT services at Wythenshawe Hospital 
Elizabeth Wilson - View Bio
0920
Expansion of P-OPAT service without a dedicated  children’s community nursing team
0940
Developing a Home OPAT Service through Cross Organisational Working
Parallel session two - Common vascular challenges
0900
tbc

Parallel session one - Respiratory disease and OPAT
1000
Tuberculosis
Helena White
1020
Non Cystic Fibrosis Bronchiectasis
Adam Hill - View Bio
1040
Q&A/Panel discussion
Parallel session two - Workshop: Practical nursing aspects of OPAT
Chair: Carol Fry / Helen Green

1100
Refreshments and networking

1130
Sponsored symposium - Baxter

Plenary session - Driving the future of OPAT in the UK
Chair: Andrew Seaton
1215
Drug stability
Tim Hills - View Bio
1235
Update to the Good Practice Recommendations & Introduction of Competencies
Ann Chapman - View Bio
1300
Re-introduction of NORS and optimising medicine agenda
Mark Gilchrist - View Bio
1315
Whats in store for 2018?
Mark Gilchrist - View Bio

1320
Closing Remarks
Andrew Seaton - View Bio